Q-omics provides the consensus-scored RPL22P3 profile across patient tissues and cancer cell-line models. RPL22P3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL22P3 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, RPL22P3 RNA expression shows 12,877 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where RPL22P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL22P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL22P3 survival associations across molecular data types. RPL22P3 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL22P3 RNA expression–survival associations across cancer types. High RPL22P3 expression shows unfavorable associations in ACC, UCEC, LUAD and LGG, but favorable associations in KIRC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL22P3 RNA expression.
This table summarizes RPL22P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL22P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL22P3 shows lower tumor expression in THCA, UCEC and KICH and higher tumor expression in LIHC, LUSC and PRAD. The LIHC box plot shows higher RPL22P3 RNA expression in tumor versus normal tissue (log2 FC = +0.214, t-test p = .001).
This table shows molecular features associated with RPL22P3 in patient tissues and cancer cell lines. In patient samples, RPL22P3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
